ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib, a third-generation TKI treatment for CML, contrasts the first and second generation TKIs due to its efficacy against the T315Z mutation variant of BCR-ABL oncogene (156).